Home / Psoriasis / Healthcare Expenditures of Psoriasis Examined

Healthcare Expenditures of Psoriasis Examined

In 2012, the top 10% (T10) of psoriasis patients accounted for nearly 40% of overall healthcare expenditures among enrollees with psoriasis in a US health plan, a recent study found. Researchers conducted a retrospective study of patients with psoriasis with continuous enrollment in a plan from January 1, 2011, to December 31, 2013. Demographics, comorbidities, prescriptions, all-cause, and psoriasis-related healthcare utilization and costs were compared between cohorts. 18,653 patients (mean age 48 years; 49% female) were included. They found:

  • Patients in the T10 group accounted for 26% (2011), 39% (2012) and 26% (2013) of all-cause costs including biologics and 13% (2011), 18% (2012) and 11% (2013) of psoriasis-related costs.
  • Mean 2012 total costs were $58,030 for T10 vs. $10,295 for B90 (all-cause) and $10,475 vs $5,301 (psoriasis-related).
  • T10 patients in 2012 filled more prescriptions and were more likely to use corticosteroids (57% vs 31%); however, biologic use and costs were similar (any use: 23% vs 24%; prescriptions: 1.5 vs 1.7, biologic costs: $4,959 vs $5,095).


Armstrong AW, Zhao Y, Herrera V, et al. Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan. [Published online ahead of print March 20, 2017]. J Dermatolog Treat. doi:10.1080/09546634.2017.1303566.

Full Article

About Dr. J. Kim

Dr Kim developed (and is continuing to develop) dermatology research news as we way from dermatologists to stay on top of the latest advances in the field of dermatology.

Check Also

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-1)

Study Description Go to  Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis. Condition or disease Intervention/treatment Phase Psoriasis Drug: Mirikizumab Drug: Placebo Phase 3 …

Leave a Reply

Your email address will not be published. Required fields are marked *